198 related articles for article (PubMed ID: 31685562)
1. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer.
Chen IM; Johansen AZ; Dehlendorff C; Jensen BV; Bojesen SE; Pfeiffer P; Bjerregaard JK; Nielsen SE; Andersen F; Holländer NH; Yilmaz MK; Rasmussen LS; Johansen JS
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):176-184. PubMed ID: 31685562
[TBL] [Abstract][Full Text] [Related]
2. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers.
Høgdall D; O'Rourke CJ; Dehlendorff C; Larsen OF; Jensen LH; Johansen AZ; Dang H; Factor VM; Grunnet M; Mau-Sørensen M; Oliveira DVNP; Linnemann D; Boisen MK; Wang XW; Johansen JS; Andersen JB
Clin Cancer Res; 2020 Nov; 26(21):5655-5667. PubMed ID: 32933994
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.
Schultz NA; Christensen IJ; Werner J; Giese N; Jensen BV; Larsen O; Bjerregaard JK; Pfeiffer P; Calatayud D; Nielsen SE; Yilmaz MK; Holländer NH; Wøjdemann M; Bojesen SE; Nielsen KR; Johansen JS
PLoS One; 2013; 8(6):e67059. PubMed ID: 23840582
[TBL] [Abstract][Full Text] [Related]
4. Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease.
Alkhateeb A; Zubritsky L; Kinsman B; Leitzel K; Campbell-Baird C; Ali SM; Connor J; Lipton A
J Gastrointest Cancer; 2014 Jun; 45(2):161-7. PubMed ID: 24446242
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40.
Palmquist C; Dehlendorff C; Calatayud D; Hansen CP; Hasselby JP; Johansen JS
Pancreas; 2020 Jan; 49(1):53-61. PubMed ID: 31856080
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases.
Peltonen R; Gramkow MH; Dehlendorff C; Osterlund PJ; Johansen JS; Isoniemi H
PLoS One; 2020; 15(8):e0236569. PubMed ID: 32756596
[TBL] [Abstract][Full Text] [Related]
7. The Assessment of Clinical Usage and Prognostic Value of YKL-40 Serum Levels in Patients With Rectal Cancer Without Distant Metastasis.
Fuksiewicz M; Kotowicz B; Rutkowski A; Achinger-Kawecka J; Wagrodzki M; Kowalska MM
Technol Cancer Res Treat; 2018 Jan; 17():1533033818765209. PubMed ID: 29642772
[TBL] [Abstract][Full Text] [Related]
8. Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer.
Rasmussen LS; Yilmaz MK; Falkmer UG; Poulsen LØ; Bøgsted M; Christensen HS; Bojesen SE; Jensen BV; Chen IM; Johansen AZ; Hansen CP; Hasselby JP; Holländer N; Nielsen SE; Andersen F; Bjerregaard JK; Pfeiffer P; Johansen JS
Eur J Cancer; 2021 Feb; 144():72-80. PubMed ID: 33341448
[TBL] [Abstract][Full Text] [Related]
9. Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer.
Hermunen K; Soveri LM; Boisen MK; Mustonen HK; Dehlendorff C; Haglund CH; Johansen JS; Osterlund P
Acta Oncol; 2020 Dec; 59(12):1416-1423. PubMed ID: 32790589
[TBL] [Abstract][Full Text] [Related]
10. Combined plasma C-reactive protein, interleukin 6 and YKL-40 for detection of cancer and prognosis in patients with serious nonspecific symptoms and signs of cancer.
Videmark AN; Christensen IJ; Feltoft CL; Villadsen M; Borg FH; Jørgensen BM; Bojesen SE; Kistorp C; Ugleholdt R; Johansen JS
Cancer Med; 2023 Mar; 12(6):6675-6688. PubMed ID: 36440611
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of YKL-40 Predicts Poor Prognosis in Patients Undergoing Curative Resection of Pancreatic Cancer.
Chen HT; Zheng JM; Zhang YZ; Yang M; Wang YL; Man XH; Chen Y; Cai QC; Li ZS
Pancreas; 2017 Mar; 46(3):323-334. PubMed ID: 28099248
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
Haas M; Laubender RP; Stieber P; Holdenrieder S; Bruns CJ; Wilkowski R; Mansmann U; Heinemann V; Boeck S
Tumour Biol; 2010 Aug; 31(4):351-7. PubMed ID: 20480409
[TBL] [Abstract][Full Text] [Related]
13. Prognostic utility of serum YKL-40 in patients with cervical cancer.
Roslind A; Palle C; Johansen JS; Christensen IJ; Nielsen HJ; Mosgaard BJ
Scand J Clin Lab Invest; 2020 Dec; 80(8):687-693. PubMed ID: 33186077
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
Haas M; Heinemann V; Kullmann F; Laubender RP; Klose C; Bruns CJ; Holdenrieder S; Modest DP; Schulz C; Boeck S
J Cancer Res Clin Oncol; 2013 Apr; 139(4):681-9. PubMed ID: 23315099
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab.
Boisen MK; Madsen CV; Dehlendorff C; Jakobsen A; Johansen JS; Steffensen KD
Int J Gynecol Cancer; 2016 Oct; 26(8):1390-8. PubMed ID: 27648712
[TBL] [Abstract][Full Text] [Related]
16. The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy.
Park H; Bang JH; Nam AR; Park JE; Jin MH; Bang YJ; Oh DY
Cancer Med; 2020 Jan; 9(1):43-51. PubMed ID: 31701645
[TBL] [Abstract][Full Text] [Related]
17. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality.
Johansen JS; Pedersen AN; Schroll M; Jørgensen T; Pedersen BK; Bruunsgaard H
Clin Exp Immunol; 2008 Feb; 151(2):260-6. PubMed ID: 18070151
[TBL] [Abstract][Full Text] [Related]
18. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure.
Harutyunyan M; Christiansen M; Johansen JS; Køber L; Torp-Petersen C; Kastrup J
Immunobiology; 2012 Jun; 217(6):652-6. PubMed ID: 22209156
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum levels of YKL 40 and CA125 as a prognostic indicators in patients with endometrial cancer.
Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Wagrodzki M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2017 Aug; 215():141-147. PubMed ID: 28624692
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
Krogh M; Christensen I; Bouwhuis M; Johansen JS; Nørgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AM; Bastholt L;
Melanoma Res; 2016 Aug; 26(4):367-76. PubMed ID: 27076041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
